Vero cells (ATCC CCL-81) were cultured in Eagle’s minimal essential medium (EMEM; Lonza) with 8 % FCS (PAA) and antibiotics. Huh7 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Lonza) containing 8 % FCS, 2 mM l -glutamine (PAA), non-essential amino acids (PAA) and antibiotics. Vero E6 and Calu3/2B4 cells were cultured as described previously (Snijder et al., 2006 (link); Yoshikawa et al., 2010 (link)). Infection of Vero, Vero E6, Huh7 and Calu3/2B4 cells with MERS-CoV (strain EMC/2012; Zaki et al., 2012; van Boheemen et al., 2012 (link)) at high m.o.i. (m.o.i. of 5) was carried out in PBS containing 50 µg DEAE-dextran ml−1 and 2 % FCS. Inoculations with a low dose (m.o.i. ≤ 0.05) of MERS-CoV or SARS-CoV (strain HKU-39849; Zeng et al., 2003 (link)) were carried out directly in EMEM containing 2 % FCS. Virus titrations by plaque assay were performed as described previously (van den Worm et al., 2012 (link)). All work with live MERS-CoV and SARS-CoV was performed inside biosafety cabinets in Biosafety Level 3 facilities at Leiden University Medical Center or Erasmus Medical Center.
>
Procedures
>
Laboratory Procedure
>
Viral Plaque Assay
Viral Plaque Assay
Viral Plaque Assay: An essential technique for quantifying infectious virus particles and evaluating antiviral agents.
This assay involves infecting cell monolayers with a virus, allowing for plaque formation, and then counting the number of plaques to determine the viral titer.
Optimizing this assay with AI-driven tools like PubCompare.ai can enhance reproducibility, accuracy, and the discovery of optimal protocols and products for your viral assay needs.
Leveraging the best available literature, pre-prints, and patents, PubCompare.ai helps locate the most effective procedures to advance your viral research.
This assay involves infecting cell monolayers with a virus, allowing for plaque formation, and then counting the number of plaques to determine the viral titer.
Optimizing this assay with AI-driven tools like PubCompare.ai can enhance reproducibility, accuracy, and the discovery of optimal protocols and products for your viral assay needs.
Leveraging the best available literature, pre-prints, and patents, PubCompare.ai helps locate the most effective procedures to advance your viral research.
Most cited protocols related to «Viral Plaque Assay»
Amino Acids, Essential
Antibiotics
Cells
DEAE-Dextran
Eagle
Glutamine
Helminths
Infection
Middle East Respiratory Syndrome Coronavirus
Severe acute respiratory syndrome-related coronavirus
Strains
Titrimetry
Vaccination
Vero Cells
Viral Plaque Assay
All procedures involving human subjects were reviewed and approved by the National Institute for Occupational Safety and Health (NIOSH) and West Virginia University (WVU) Institutional Review Boards. Written informed consent was obtained from all study participants.
Volunteer subjects were recruited from patients presenting with influenza-like symptoms at the student health clinic of WVU in Morgantown, West Virginia, USA, during October and November of 2009. After providing informed consent, each subject was given a rapid influenza test (QuickVue Influenza A+B test, Quidel). The rapid test was used to provide an initial estimate of influenza case numbers; however, because the sensitivity of the test was reported to be low [23] (link), subjects were allowed to continue participating in the study regardless of the outcome. Two nasopharyngeal mucus swabs were collected for analysis by qPCR and viral plaque assay (VPA), the subject's oral temperature was taken, and the subject was asked to answer a brief health questionnaire.
Cough-generated aerosols from the volunteer subjects were collected using the cough aerosol particle collection system (Figure 3 ) similar to that described previously [24] . The system consisted of an ultrasonic spirometer (Easy One, NDD Medical Technologies) and a 10 liter piston-style spirometer (SensorMedics model 762609) modified to allow aerosol collection using a NIOSH two-stage cyclone aerosol sampler [6] (link) or an SKC BioSampler with a 5 ml collection vessel (#225-9593, SKC). The NIOSH sampler collected cough aerosol particles in a 15 ml centrifuge tube (stage 1; #35-2096, Falcon), a 1.5 ml centrifuge tube (stage 2; #02-681-339, Fisher Scientific) and a 37 mm polytetrafluoroethylene (PTFE) filter with 2 µm pores (#225-27-07, SKC). The NIOSH sampler conforms to the ACGIH/ISO criteria for respirable particle sampling [25] . The flow rate through each NIOSH sampler was set to 3.5 liters/minute with a flow calibrator (Model 4143, TSI) before use. The SKC BioSampler collects aerosols into 5 ml of universal transport media (UTM; Copan Diagnostics) at 12.5 liters/minute.
Before each collection, the system was purged and the piston spirometer was partially filled with 5 liters of clean dry air. The subject was then asked to sit in front of the system, inhale, exhale, inhale as deeply as possible, seal their mouth around the mouthpiece, and cough into the machine using as much of the air in their lungs as possible. After each cough, the system valve was closed and the cough-generated aerosol was collected using the aerosol sampler. This procedure was repeated twice for a total of three coughs from each subject.
After collection, the nasopharyngeal swabs were immersed in 1 ml UTM in a storage tube. For the NIOSH samplers, 1 ml of UTM was added to each sampler tube, while the sampler filters were immersed in 1 ml UTM in a 50 ml centrifuge tube. For the SKC sampler, the UTM collection media was removed from the sampler and placed a storage tube. All tubes were vortexed thoroughly. 500 µl of UTM was then drawn from each tube and mixed with 500 µl of Lysis/Binding Solution Concentrate (LBSC; Ambion) in fresh tubes. The tubes with the remaining UTM were stored overnight at 4°C, while the tubes with UTM and LBSC were stored overnight at −20°C. In some cases, UTM was not used; instead, 500 µl of LBSC was added directly to each tube, and the tubes were stored overnight at −20°C.
To extract the sample RNA, tubes containing samples in LBSC were thawed, carrier RNA (Ambion) was added to enhance RNA extraction and XenoRNA (Applied Biosystems) was added as a qPCR internal control. Total RNA was extracted as previously reported [6] (link) and immediately transcribed into cDNA using High Capacity RNA to cDNA Master Mix (Applied Biosystems).
Real-time quantitative PCR was performed with a Model 7500 Fast Real-Time PCR system (Applied Biosystems) using influenza A matrix-specific primers and probe (Spackman, 2002).
To determine the relative genome copy from seasonal influenza A-positive aerosol samples, a standard curve was generated from 10-fold serial dilutions of the influenza M1 matrix gene and analyzed alongside all qPCR reactions. All reactions were run in duplicate. A negative control without template was included in all real-time PCR reactions. Real-time PCR detection of the XenoRNA internal control was performed using the XenoRNA Control TaqMan Gene Expression Assay from the TaqMan Cells to Ct Control Kit (Applied Biosystems). The internal controls were amplified in all samples.
For the viral plaque assay (VPA), Madin Darby canine kidney (MDCK) cells (CCL-34) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cells were propagated and maintained in 75-cm2 flasks (Corning CellBind Surface, Corning, NY). Growth medium for MDCK cells consisted of Eagle's minimal essential medium (EMEM, ATCC) supplemented with 10% fetal bovine serum (Hyclone Laboratories, Inc, Logan, Utah), 0.4 units/ml penicillin (Invitrogen, Carlsbad, CA), and 0.4 µg/ml streptomycin (Invitrogen). Cells were incubated at 35°C in a humidified 5% CO2 incubator until about 90% confluent. The VPA was performed by trypsinizing, washing and plating MDCK cells at a density of 2.0×106 per well (CoStar 6-well tissue culture plate, Corning). Cells were incubated at 35°C in a humidified 5% CO2 incubator overnight. Confluent cellular monolayers were next washed two times with PBS (Invitrogen) and treated with the clinical samples. Following 45 min of adsorption, virus-infected MDCK cells were washed with phosphate buffered saline (PBS, Gibco), overlaid with an agarose medium solution and incubated at 35°C in a humidified 5% CO2 incubator for 48 h. Plaques were visually enumerated and plaque forming units (PFU)/ml were calculated.
Initially, VPA's were performed only on nasopharyngeal swabs and cough aerosols from subjects with positive rapid influenza tests. After a few days, our preliminary results indicated that the rapid tests had a lower-than-expected sensitivity, and we changed our methodology to perform VPA's on all samples.
Volunteer subjects were recruited from patients presenting with influenza-like symptoms at the student health clinic of WVU in Morgantown, West Virginia, USA, during October and November of 2009. After providing informed consent, each subject was given a rapid influenza test (QuickVue Influenza A+B test, Quidel). The rapid test was used to provide an initial estimate of influenza case numbers; however, because the sensitivity of the test was reported to be low [23] (link), subjects were allowed to continue participating in the study regardless of the outcome. Two nasopharyngeal mucus swabs were collected for analysis by qPCR and viral plaque assay (VPA), the subject's oral temperature was taken, and the subject was asked to answer a brief health questionnaire.
Cough-generated aerosols from the volunteer subjects were collected using the cough aerosol particle collection system (
Before each collection, the system was purged and the piston spirometer was partially filled with 5 liters of clean dry air. The subject was then asked to sit in front of the system, inhale, exhale, inhale as deeply as possible, seal their mouth around the mouthpiece, and cough into the machine using as much of the air in their lungs as possible. After each cough, the system valve was closed and the cough-generated aerosol was collected using the aerosol sampler. This procedure was repeated twice for a total of three coughs from each subject.
After collection, the nasopharyngeal swabs were immersed in 1 ml UTM in a storage tube. For the NIOSH samplers, 1 ml of UTM was added to each sampler tube, while the sampler filters were immersed in 1 ml UTM in a 50 ml centrifuge tube. For the SKC sampler, the UTM collection media was removed from the sampler and placed a storage tube. All tubes were vortexed thoroughly. 500 µl of UTM was then drawn from each tube and mixed with 500 µl of Lysis/Binding Solution Concentrate (LBSC; Ambion) in fresh tubes. The tubes with the remaining UTM were stored overnight at 4°C, while the tubes with UTM and LBSC were stored overnight at −20°C. In some cases, UTM was not used; instead, 500 µl of LBSC was added directly to each tube, and the tubes were stored overnight at −20°C.
To extract the sample RNA, tubes containing samples in LBSC were thawed, carrier RNA (Ambion) was added to enhance RNA extraction and XenoRNA (Applied Biosystems) was added as a qPCR internal control. Total RNA was extracted as previously reported [6] (link) and immediately transcribed into cDNA using High Capacity RNA to cDNA Master Mix (Applied Biosystems).
Real-time quantitative PCR was performed with a Model 7500 Fast Real-Time PCR system (Applied Biosystems) using influenza A matrix-specific primers and probe (Spackman, 2002).
To determine the relative genome copy from seasonal influenza A-positive aerosol samples, a standard curve was generated from 10-fold serial dilutions of the influenza M1 matrix gene and analyzed alongside all qPCR reactions. All reactions were run in duplicate. A negative control without template was included in all real-time PCR reactions. Real-time PCR detection of the XenoRNA internal control was performed using the XenoRNA Control TaqMan Gene Expression Assay from the TaqMan Cells to Ct Control Kit (Applied Biosystems). The internal controls were amplified in all samples.
For the viral plaque assay (VPA), Madin Darby canine kidney (MDCK) cells (CCL-34) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cells were propagated and maintained in 75-cm2 flasks (Corning CellBind Surface, Corning, NY). Growth medium for MDCK cells consisted of Eagle's minimal essential medium (EMEM, ATCC) supplemented with 10% fetal bovine serum (Hyclone Laboratories, Inc, Logan, Utah), 0.4 units/ml penicillin (Invitrogen, Carlsbad, CA), and 0.4 µg/ml streptomycin (Invitrogen). Cells were incubated at 35°C in a humidified 5% CO2 incubator until about 90% confluent. The VPA was performed by trypsinizing, washing and plating MDCK cells at a density of 2.0×106 per well (CoStar 6-well tissue culture plate, Corning). Cells were incubated at 35°C in a humidified 5% CO2 incubator overnight. Confluent cellular monolayers were next washed two times with PBS (Invitrogen) and treated with the clinical samples. Following 45 min of adsorption, virus-infected MDCK cells were washed with phosphate buffered saline (PBS, Gibco), overlaid with an agarose medium solution and incubated at 35°C in a humidified 5% CO2 incubator for 48 h. Plaques were visually enumerated and plaque forming units (PFU)/ml were calculated.
Initially, VPA's were performed only on nasopharyngeal swabs and cough aerosols from subjects with positive rapid influenza tests. After a few days, our preliminary results indicated that the rapid tests had a lower-than-expected sensitivity, and we changed our methodology to perform VPA's on all samples.
Adsorption
Aerosols
Biological Assay
Biological Models
Blood Vessel
CCL 34
Cells
Cough
Cyclonic Storms
Dental Plaque
Diagnosis
DNA, Complementary
Ethics Committees, Research
Fetal Bovine Serum
Gene Expression
Genes
Genome
Hypersensitivity
Inhalation
Lung
Madin Darby Canine Kidney Cells
Mucus
Nasopharynx
Oligonucleotide Primers
Oral Cavity
Patients
Penicillins
Phocidae
Phosphates
Polytetrafluoroethylene
Real-Time Polymerase Chain Reaction
Safety
Saline Solution
Senile Plaques
Sepharose
Spirometry
Streptomycin
Student
Technique, Dilution
Test, Quick
Tissues
Ultrasonics
Viral Plaque Assay
Virus
Virus Vaccine, Influenza
Voluntary Workers
MRE16-eGFP and TR339-eGFP virus stocks were generated from SINV infectious cDNA clones with inserts of enhanced GFP (eGFP) driven by the second sub-genomic promoter, using standard methods [35 (link),46 (link),47 (link)]. MRE16-eGFP was passed once in baby hamster kidney (BHK-21) cells and twice in Aedes albopictus clone C6/36 cells. TR339 5'2J-eGFP was passed once in BHK-21 cells and three times in C6/36 cells.
For mosquito feedings, all viruses were diluted as indicated in de-fibrinated sheep blood and provided at 37°C in a water jacketed artificial feeder with parafilm membrane. An aliquot of each SINV stock was titered by viral plaque assay on Vero cells and the other aliquots were stored at -80°C and diluted prior to feeding. TR339-eGFP blood-meals contained approximately 3.3 × 108 pfu/ml and MRE16 meals contained 2.2 × 107 pfu/ml. Representative mosquitoes from each group were selected for dissection and eGFP detection with an Olympus epi-fluorescence microscope to confirm midgut infection with each batch of virus. Viral titers from individual mosquitoes were determined by plaque assays of filtered mosquito homogenates as previously described [29 (link)].
For mosquito feedings, all viruses were diluted as indicated in de-fibrinated sheep blood and provided at 37°C in a water jacketed artificial feeder with parafilm membrane. An aliquot of each SINV stock was titered by viral plaque assay on Vero cells and the other aliquots were stored at -80°C and diluted prior to feeding. TR339-eGFP blood-meals contained approximately 3.3 × 108 pfu/ml and MRE16 meals contained 2.2 × 107 pfu/ml. Representative mosquitoes from each group were selected for dissection and eGFP detection with an Olympus epi-fluorescence microscope to confirm midgut infection with each batch of virus. Viral titers from individual mosquitoes were determined by plaque assays of filtered mosquito homogenates as previously described [29 (link)].
Aedes
Biological Assay
BLOOD
Cells
Clone Cells
Culicidae
Dental Plaque
Dissection
DNA, Complementary
Genome
Hamsters
Infant
Infection
Kidney
Microscopy, Fluorescence
Sheep
Tissue, Membrane
Vero Cells
Viral Plaque Assay
Virus
Virus Diseases
We determined the titer of neutralizing antibodies by a standard plaque reduction neutralization titer (PRNT) assay using either BHK21 or SW13 cells23 (link). Results were plotted and the titers for 50% (PRNT50) and 90% inhibition (PRNT90) were calculated. The inhibition assay with J774.2 mouse macrophages was performed as follows: we mixed medium and E16 or E24 (2.5 μg of monoclonal antibody) with 5 × 102 PFU of WNV, incubated the mixture for 1 h at 4 °C, and then added to 5 × 104 J774.2 mouse macrophages in individual wells of a 24-well plate. After 1 h, cells were washed four times with PBS to remove free virus and monoclonal antibody, DMEM with 10% FBS was added, and the cells were incubated for an additional 24 h. We subsequently harvested supernatants for a viral plaque assay on Vero cells.
Antibodies, Neutralizing
Biological Assay
Cells
Macrophage
Monoclonal Antibodies
Mus
Psychological Inhibition
Senile Plaques
Vero Cells
Viral Plaque Assay
Virus
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Animals
Antibiotics
Biological Assay
Cells
Clone Cells
Dental Plaque
Drug Overdose
Esterases
Females
Fetus
Freezing
Hemorrhage
Homo sapiens
Institutional Animal Care and Use Committees
Isoflurane
Ketamine
Lung
Mus
Phenotype
Plethysmography, Whole Body
SARS-CoV-2
Senile Plaques
Sepharose
Serum
Technique, Dilution
Therapeutics
Titrimetry
Vero Cells
Viral Plaque Assay
Virus Replication
Xylazine
Most recents protocols related to «Viral Plaque Assay»
BALB/c mice (four-week-old, female) were purchased from Japan SLC (Shizuoka, Japan). The mice were divided into three groups with nine animals in each group. Mice were anesthetized and inoculated intranasally (20 µL) of rD/OK or rD/OK-AL (1.0 × 105 PFU), respectively. Organs containing nasal turbinates, the tracheas, and the lungs were collected after three and six days following inoculation and homogenized in phosphate-buffered saline (PBS) for virus titration via the plaque assay.
Animals
Females
Lung
Mice, House
Mice, Inbred BALB C
Phosphates
Saline Solution
Titrimetry
Trachea
Turbinates
Vaccination
Viral Plaque Assay
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Biological Assay
Cultured Cells
Infection
Response, Immune
SARS-CoV-2
SARS-CoV-2 B.1.351 variant
SARS-CoV-2 BA.1 variant
Strains
Sucrose
Viral Plaque Assay
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
A549 Cells
Antibodies
Biological Assay
Cells
CR3022
Formaldehyde
Methylcellulose
Monoclonal Antibodies
Rabbits
SARS-CoV-2
Senile Plaques
Serum
Vero Cells
Violet, Gentian
Viral Plaque Assay
Viscosity
Viral plaque assays were performed on body fluid samples (blood, sputum, urine, pleural fluid) collected from patients immediately before and 24, 48, 72, and 96 hours after Olvi-vec treatment to assess for the presence of viral particles. Post-treatment tumor biopsies collected 2-5 days after treatment also underwent assessment for viral particles using viral plaque assays. In brief, patient samples were plated on confluent layers of CV-1 cells. Evaluation of virus infection was done by visual assessment of viral plaque in wells with both CV-1 cells and patient samples. Additionally, post-treatment serum samples obtained from patients 60 days after Olvi-vec treatment were assessed for the presence of Olvi-vec neutralizing antibodies via standard vaccinia virus neutralization assay and compared to corresponding pre-treatment serum samples.
Aftercare
Antibodies, Neutralizing
Biological Assay
Biopsy
BLOOD
Body Fluids
Cells
Dental Plaque
Neoplasms
Patients
Pleura
Serum
Specimen Handling
Sputum
Urine
Vaccinia virus
Viral Plaque Assay
Virion
Virus Diseases
Time-of-drug addition were performed to explore which steps of the ILHV replication cycle are blocked by caffeic acid. Briefly, CA was added to the virus and/or host cells at different times before, during, and after viral inoculation into the cells as follows (Figure 1 ): (1) pre-treatment of virus followed by inoculation of the treated virus into the cells investigates whether CA has virucidal or neutralizing activity; (2) pre-treatment of the cells with CA before viral inoculation explores whether this substance could block the viral receptor, inhibiting viral attachment to the host cells, or if it could induce production of antiviral host factors; (3) co-treatment of cells and virus during virus inoculation examines the function of CA during the steps of virus entry, including virucidal (neutralizing) activity and blockade of viral attachment and penetration into the cells; (4) treatment of virus-infected cells during the entire post-inoculation period investigates the antiviral effects of CA during post-entry steps such as genome translation and replication, virion assembly, and virion release from the cells. Viral infection experiments were performed in A549, HepG2, or Vero cells seeded in 24-well plates treated with CA or untreated controls. Under the different conditions described above, the cells were infected with MOI 1 of ILHV for one hour at 37 °C and revealed through the virus plaque-forming assay titration of supernatant or cell content (described in Section 2.4 ). Three independent experiments with quadruplicate measurements were performed. Data were analyzed by four-parameter curve fitting from a dose–response curve using GraphPad Prism (version 8.00) to calculate EC50 (concentration of the compound that inhibited 50% of the infection), and the selectivity index for the compound was calculated as the CC50:EC50 ratio.
Antiviral Agents
caffeic acid
Cells
DNA Replication
Genetic Selection
Genome
Infection
Parainfluenza Virus 2, Human
Pharmaceutical Preparations
prisma
Receptors, Virus
Somatostatin-Secreting Cells
Titrimetry
Vaccination
Vero Cells
Viral Plaque Assay
Viral Vaccines
Virion
Virus
Virus Assembly
Virus Attachment
Virus Diseases
Virus Internalization
Top products related to «Viral Plaque Assay»
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, Germany, China, Japan, United Kingdom, France, Sao Tome and Principe, Italy, Australia, Macao, Spain, Switzerland, Canada, Belgium, Poland, Brazil, Portugal, India, Denmark, Israel, Austria, Argentina, Sweden, Ireland, Hungary
Crystal violet is a synthetic dye commonly used in laboratory settings. It is a dark purple crystalline solid that is soluble in water and alcohol. Crystal violet has a variety of applications in the field of microbiology and histology, including as a staining agent for microscopy and in the gram staining technique.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
Sourced in United States, Germany, France, Italy, Japan, India, Brazil, United Kingdom, Hong Kong, Australia
Vero E6 cells are a continuous cell line derived from the kidney of the African green monkey (Cercopithecus aethiops). They are widely used in various applications, including virus propagation, cytotoxicity assays, and vaccine development.
Sourced in United States, United Kingdom, Germany, France, Canada, Switzerland, Italy, Australia, Belgium, China, Japan, Austria, Spain, Brazil, Israel, Sweden, Ireland, Netherlands, Gabon, Macao, New Zealand, Holy See (Vatican City State), Portugal, Poland, Argentina, Colombia, India, Denmark, Singapore, Panama, Finland, Cameroon
L-glutamine is an amino acid that is commonly used as a dietary supplement and in cell culture media. It serves as a source of nitrogen and supports cellular growth and metabolism.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
Sourced in United States, Germany, United Kingdom, Japan, Belgium, Switzerland, Italy, Australia, Canada, China, Sao Tome and Principe, Poland, Israel, France, Spain, Austria
Methylcellulose is a water-soluble, synthetic polymer derived from cellulose. It is a white, odorless, and tasteless powder that is commonly used as a thickening, stabilizing, and emulsifying agent in various industries, including pharmaceutical, food, and personal care products.
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
Sourced in United States, Germany, Japan, United Kingdom, China
Vero cells are a cell line derived from the kidney of a normal adult African green monkey. They are epithelial-like cells and widely used in research, vaccine production, and viral infection studies.
Sourced in United States
Low melting agarose is a type of gel matrix material used in various laboratory applications. It has a lower melting point compared to standard agarose, allowing for gentler handling and processing of sensitive biological samples.
More about "Viral Plaque Assay"
Viral Plaque Assay is a crucial technique for quantifying infectious viral particles and evaluating antiviral agents.
This assay involves infecting cell monolayers, typically Vero or Vero E6 cells, with a virus and allowing for plaque formation.
Plaques are then counted to determine the viral titer.
Optimizing this assay with AI-driven tools like PubCompare.ai can enhance reproducibility, accuracy, and the discovery of optimal protocols and products.
The Viral Plaque Assay often utilizes various media and reagents, such as Dulbecco's Modified Eagle Medium (DMEM), Fetal Bovine Serum (FBS), L-glutamine, Penicillin, Streptomycin, and methylcellulose or low melting agarose for overlay.
These components help support cell growth and viral replication, as well as visualize the plaques through staining techniques like Crystal violet.
Leveraging the best available literature, preprints, and patents, PubCompare.ai helps researchers locate the most effective procedures to advance their viral research.
By comparing and evaluating different protocols, the platform can identify the optimal conditions and products for enhancing the reproducibility and accuracy of the Viral Plaque Assay.
This can lead to more reliable and efficient viral quantification and antiviral agent evaluation, ultimately accelerating the progress of viral research and drug development.
This assay involves infecting cell monolayers, typically Vero or Vero E6 cells, with a virus and allowing for plaque formation.
Plaques are then counted to determine the viral titer.
Optimizing this assay with AI-driven tools like PubCompare.ai can enhance reproducibility, accuracy, and the discovery of optimal protocols and products.
The Viral Plaque Assay often utilizes various media and reagents, such as Dulbecco's Modified Eagle Medium (DMEM), Fetal Bovine Serum (FBS), L-glutamine, Penicillin, Streptomycin, and methylcellulose or low melting agarose for overlay.
These components help support cell growth and viral replication, as well as visualize the plaques through staining techniques like Crystal violet.
Leveraging the best available literature, preprints, and patents, PubCompare.ai helps researchers locate the most effective procedures to advance their viral research.
By comparing and evaluating different protocols, the platform can identify the optimal conditions and products for enhancing the reproducibility and accuracy of the Viral Plaque Assay.
This can lead to more reliable and efficient viral quantification and antiviral agent evaluation, ultimately accelerating the progress of viral research and drug development.